NEW YORK (GenomeWeb) – OncoCyte today announced that it has closed a $6.6 million financing round that included a cash investment of $3.3 million and the conversion of $3.3 million of existing debt into equity.

All of OncoCyte's existing shareholders participated in the financing round, the firm said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed. reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.